Letrozole vs GnRH Antagonist in Ovarian Aging IVF

Why It Matters

Optimizing stimulation protocols for older patients can boost IVF efficiency while lowering treatment costs, directly affecting clinic profitability and patient access to care.

Key Takeaways

• Letrozole cuts gonadotropin use by ~20%
• GnRH antagonist matches implantation rates
• Letrozole enhances mature oocyte count in >38
• Protocol choice influences overall IVF cost

Pulse Analysis

Ovarian aging remains a primary challenge in assisted reproductive technology, as declining follicular reserve and oocyte quality reduce success rates. Letrozole, an aromatase inhibitor, has emerged as a cost‑effective alternative to conventional GnRH antagonist protocols by suppressing estrogen synthesis and enhancing endogenous follicle‑stimulating hormone activity. This mechanism allows clinicians to achieve comparable follicular recruitment with fewer exogenous gonadotropins, a benefit that is especially valuable for women over 35 whose ovarian response is often blunted.

The recent multicenter trial involving 1,200 IVF cycles demonstrated that letrozole‑based stimulation yielded a 15‑20% increase in mature (MII) oocytes and a modest reduction in total medication dosage, while clinical pregnancy and live‑birth rates remained statistically indistinguishable from those achieved with GnRH antagonists. Patients on the antagonist regimen experienced slightly higher estradiol peaks, which may increase the risk of ovarian hyperstimulation syndrome in susceptible individuals. Conversely, the letrozole group reported lower incidence of adverse hormonal side effects, translating into improved patient comfort and adherence.

For fertility clinics, these findings underscore the importance of protocol personalization. Letrozole offers a financially attractive option, reducing drug spend and potentially expanding access for cost‑sensitive patients. However, GnRH antagonists retain relevance for cases requiring tighter control of luteinizing hormone surges or when estrogen levels must be tightly regulated. Ongoing research into biomarkers of ovarian reserve will further refine protocol selection, positioning both letrozole and GnRH antagonists as complementary tools in the evolving landscape of age‑related IVF treatment.